AgeneBio

Quick facts

Phase 2 pipeline

• AGB101 · Neurology
  AGB101 is a monoclonal antibody targeting amyloid-beta

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AgeneBio portfolio CI brief
• AgeneBio pipeline updates RSS